JPRN-UMIN000048653已完成未知
Efficacy and Safety of the fourth dose of mRNA COVID-19 Vaccine in healthy volunteers: An observational study. - COVID-19 Vaccine 4th study
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Those deemed inappropriate for participation in the study by the investigator 2) Patients with a history of or coexisting with immunosuppressive medication, autoimmune diseases (systemic lupus erythematosus, Sjogren's syndrome, dermatomyositis/polymyositis, mixed connective tissue disease, systemic scleroderma, rheumatoid arthritis, polymyalgia rheumatica, psoriatic arthritis, spondyloarthritis and its related diseases, vasculitis syndrome, inflammatory bowel disease, Guillain-Barre syndrome, neuromyelitis optica) Multiple sclerosis, neuromyelitis optica). 3) Patients with a history of COVID-19 4) Inability to communicate
研究者
相似试验
已完成
不适用
Efficacy and Safety of the third dose of mRNA COVID-19 Vaccine in healthy volunteers: An observational study.JPRN-UMIN000046211Kobe City Medical Center General Hospital, Department of Hematology30
已完成
4 期
Safety and efficacy of the 3rd and the 4th dose of mRNA COVID19 vaccine in kidney transplant recipientsCOVID19 vaccination responseKidney transplant recipientsInfection - Studies of infection and infectious agentsRespiratory - Other respiratory disorders / diseasesACTRN12622001106729Martin Kacer126
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine in Thai population.After the third dose of the COVID-19 vaccine, the immune response in healthy volunteers who received 2 doses of COVID19 vaccine (CoronaVac or ChAdOx1) at least three months.COVID-19 vaccine, Third dose, ChAdOx1, coronavac, Sinovac, BNT162b2, SinopharmTCTR20210731004Chulabhorn Royal Academy5,520
招募中
2 期
Immunogenicity and safety of the third dose COVID-19 vaccine via intradermal compare with intramuscular administration (Randomized controlled trial)The immune response after the third dose of the COVID-19 vaccine via intradermal administration in healthy volunteers.COVID-19 vaccine, Third dose, intradermal, ChAdOx1, coronavac, Sinovac, BNT162b2, mRNA1263, SinopharmTCTR20210731003Chulabhorn Royal Academy960
已完成
1 期
AcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-IIAcquired immunodeficiency syndrome (AIDS)Acquired Immunodeficiency SyndromeImmunologic Deficiency SyndromesLentivirus InfectionsRetroviridae InfectionsRNA Virus InfectionsSexually Transmitted Diseases, ViralSlow Virus DiseasesImmune System DiseasesSexually Transmitted DiseasesHIV InfectionsRPCEC00000213Center of Molecular Immunology (CIM)25